Browsing Tag
Oncology
318 posts
Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq:…
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally…
Zephyr AI announces $111m Series A to advance AI in precision medicine
Zephyr AI, Inc., a pioneering healthcare technology company committed to enhancing precision medicine through fast and explainable Artificial…
Eris Lifesciences acquires Biocon Biologics’ branded formulation business for Rs 1,242cr
In a strategic move that reshapes the landscape of India’s injectables market, Eris Lifesciences Ltd., a leading player…
Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible
In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name…
CureMatch, Spesana forge partnership to revolutionize precision medicine
In a groundbreaking development for the healthcare industry, CureMatch and Spesana have announced a strategic partnership aimed at…
Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML
Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology,…
Kinnate Biopharma agrees to merger with XOMA, boosting shareholder value and advancing cancer research
Kinnate Biopharma Inc. (Nasdaq: KNTE), a leading clinical-stage precision oncology company, has announced a definitive merger agreement with…
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals,…
G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned
In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in…